Please assess the completion status of the following clinical trial:

Trial Title: Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Heart failure as defined by at least one of symptom (paroxysmal nocturnal dyspnea; orthopnea; or dyspnea on mild or moderate exertion) at the time of screening and at least one sign (any rales post cough; jugular venous pressure(JVP) greater than or equal to 10cm of water(H2O); lower extremity edema; or chest x-ray demonstrating pleural effusion, pulmonary congestion, or cardiomegaly) within 12 months prior to study entry:~* left ventricular ejection fraction greater than or equal to 45% (per local reading); the ejection fraction must have been obtained within 6 months prior to randomization and after any MI or other event that would affect ejection fraction~* Controlled systolic blood pressure(BP), defined as a target systolic BP less than 140 mm Hg; participants with BP up to and including 160 mm Hg are eligible for enrollment if they are on three or more medications to control BP~* Serum potassium less than 5.0 mmol/L prior to randomization~* At least one hospital admission for which heart failure was a major component of the hospitalization some time within the 12 months prior to study entry OR brain natriuretic peptide (BNP) greater than or equal to 100pg/ml or N-terminal pro-BNP greater than or equal to 360pg/ml within the 60 days prior to study entry~* Women of child-bearing potential must have a negative serum/urine pregnancy test within 72 hours prior to randomization, must not be lactating, and must agree to use an effective method of contraception during the entire course of study participation~* Willing to comply with scheduled visits~* Informed consent form signed by the subject prior to participation in the trial~EXCLUSION CRITERIA:~* Severe systemic illness with an expected life expectancy of less than 3 years~* Chronic pulmonary disease requiring home O2, oral steroid therapy, or hospitalization for exacerbation within 12 months of study entry, or significant chronic pulmonary disease in the opinion of the investigator~* Known infiltrative or hypertrophic obstructive cardiomyopathy or known pericardial constriction~* Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery during the trial~* Atrial fibrillation with a resting heart rate greater than 90 bpm~* MI in the past 90 days~* Coronary artery bypass graft surgery in the past 90 days~* Percutaneous coronary intervention in the past 30 days~* Heart transplant recipient~* Currently implanted left ventricular assist device~* Stroke in past 90 days~* Systolic BP (SBP) greater than 160 mm Hg~* Known orthostatic hypotension~* Gastrointestinal disorder that could interfere with study drug absorption~* Use of any aldosterone antagonist or potassium sparing medication in the last 14 days or any known condition that would require the use of an aldosterone antagonist during study participation;~* Known intolerance to aldosterone antagonists~* Current lithium use~* Current participation (including prior 30 days) in any other therapeutic trial~* Any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol~* History of hyperkalemia (serum potassium greater than or equal to 5.5mmol/L) in the past 6 months or serum potassium greater than or equal to 5.0mmol/L within the past 2 weeks~* Severe renal dysfunction, defined as an estimated glomerular filtration rate(GFR) less than 30ml/min. Participants with serum creatinine greater than or equal to 2.5mg/dl are also excluded even if their GFR is greater than or equal to 30ml/min~* Known chronic hepatic disease, defined as aspartate aminotransferase(AST) and alanine aminotransferase(ALT) levels greater than 3.0 times the upper limit of normal as read at the local lab.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of spironolactone
- Spironolactone (Type: EXPERIMENTAL): Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete